Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman Served as Counsel to Tharimmune, Inc. in its $545 Million Private Placement

Tharimmune, Inc. (NASDAQ: THAR) a publicly traded company that will leverage the Canton Coin (“CC”) to support the Canton Network’s ability to digitize traditional financial markets, announced the successful close of its previously announced private placement for the purchase and sale of shares of common stock (or par-value pre-funded warrants in lieu thereof) at a price of $3.075 per share, resulting in aggregate gross proceeds of approximately $545 million.

Tharimmune intends to use the net proceeds to acquire Canton Coin (“CC”), the utility token supporting interoperability and settlement across the Canton Network, and to support its plans to operate as a Super Validator and run additional Validators on the Canton Network. Remaining proceeds will be used for working capital and general corporate purposes.

Participating investors included ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Fairmint Inc., Feynman Point Asset Management, Five North, IntellectEU, Kaiko, Kenetic, Kraken, LendOS, Lukka, MPCH, Nima Capital, Obsidian Software, Polychain Capital, Proof Group, SBI Group, The Tie, Tradeweb Markets, and 7RIDGE. The Canton Foundation also participated, making Tharimmune the first publicly traded company supported by the Foundation.

In connection with the transaction, Tharimmune appointed Mark Wendland, former Partner and Chief Operating Officer at DRW, as Chief Executive Officer. Mark Toomey, former Managing Director and Head of Business Development at Liberty City Ventures, was appointed President. Mr. Wendland also joined the Company’s Board of Directors, while the existing management team continues to oversee Tharimmune’s clinical-stage biotechnology operations.

Lucosky Brookman LLP and Sheppard Mullin Richter & Hampton LLP served as counsel to Tharimmune. Clear Street acted as sole placement agent and a financial advisor in connection with the Offering. President Street Global served as a financial advisor in connection with the Offering. Paul Hastings LLP served as counsel to Clear Street. Reed Smith LLP served as counsel to DRW.

Related Professionals: Joseph Lucosky, Peter Campitiello, Scott Linsky, Federica Pantana, Rani HaCohen, and Juliana Pigna, Esq.